Welcome to the Settlement website for the Clovis Securities Litigation (Medina, et al. v. Clovis Oncology, Inc., et al., Civil Action No. 1:15-cv-02546-RM-MEH), pending in the United States District Court for the District of Colorado (the “Action”).
The Court-appointed Lead Plaintiff, M.Arkin (1999) LTD and Arkin Communications LTD, has reached a settlement of this Action with defendants Clovis Oncology, Inc. ("Clovis"), Patrick J. Mahaffy, Erle T. Mast, Andrew Allen, and Gillian Ivers-Read for $142 million, with $25 million paid in cash and $117 million paid in shares of Clovis common stock (the “Settlement”). The Settlement resolves all claims in the Action.
Following a hearing on October 26, 2017, the Court entered a Judgment approving the Settlement as fair, reasonable and adequate, and entered an order approving Lead Counsel’s motion for attorneys’ fees and reimbursement of expenses.
If you are a member of the Settlement Class, your rights will be affected and you may be eligible for a payment from the Settlement. The Settlement Class consists of:
All persons and entities who or which (i) purchased or otherwise acquired Clovis common stock and/or (ii) purchased or otherwise acquired exchange traded call options on Clovis common stock and/or sold/wrote exchange traded put options on Clovis common stock, between May 31, 2014 and April 7, 2016, inclusive (the “Class Period”), and who were damaged thereby.